gastric cancer
ALK Inhibitors Show Benefit in Subset of GI Cancers, Strengthening Tissue-Agnostic Potential
Premium
Researchers urged other oncologists to look for ALK rearrangements in GI patients and try to get them on ALK inhibitors through trials or compassionate use programs.
The company is conducting a clinical trial of a pan-variant inhibitor for KIT-mutant GIST and hopes to advance an EGFR pan-variant inhibitor to the clinic soon.
Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors
European regulators approved the agent for PD-L1-positive cervical cancer and for five tumor types defined by high microsatellite instability or DNA mismatch repair deficiency.
AstraZeneca Licenses Claudin18.2, CD3 Antibody from Harbour BioMed in $350M Deal
The drug has shown activity in wild-type and mutated Claudin18.2-positive gastric cancer and pancreatic cancer in preclinical studies.
Innovent Begins Phase I Trial of IBI389 in Claudin18.2-Expressing Solid Tumors
In the dose expansion phase of the study, researchers will enroll patients with Claudin18.2-expressing pancreatic, gastric, and other solid tumors.